The Sensitivity and Specificity of Canine Detection of Parkinson's Disease

September 21, 2021 updated by: Chang-Qing Gao, Central South University

The Sensitivity and Specificity of Sniffer Dogs for Diagnosis of Parkinson's Disease: Diagnostic Accuracy Study

People sometimes report that their relatives who have been diagnosed with Parkinson's disease (PD) have a unique smell. A previous study has demonstrated that PD patients do have smell that is different from that of healthy people. Sniffer dogs have long been used to identify criminals, and recently been used to identify subject with cancer. The investigators hypothesized that sniffer dogs may be able to identify PD patients.

Study Overview

Status

Completed

Conditions

Detailed Description

Parkinson's Disease is a neurodegeneration disorder that affects the life of millions of people worldwide. There are multiple drugs available now that can modify the process of the disease. Making a timely and correct diagnosis of PD is still a great challenge in many cases even for specialists. Correct diagnosis is fundamental to the appropriate administration of medicines. To help clinicians to quickly and correctly make a diagnosis, the investigators aim to use sniffer dogs to identify PD patients from clearly non-PD subjects. After more than one-year training of the dogs, the investigators found that it is feasible to use dogs to identify PD patients from non-PD subjects. Now the investigators are trying to estimate the sensitivity and specificity of sniffer dogs in identifying PD patients from non-PD subjects.

In this multicenter study, the clinicians and their assistants will collect samples and send to the study center. One researcher alone will put seven plastic bags containing matched samples (one PD sample and six non-PD samples) on a table and take notes, then relabel them with random numbers and take notes again, and keep them in a confidential place till the study is completed. Another researcher will take over the relabeled samples and put them into different tanks and take notes. Thus, both the experimenter who helps to place the samples into tanks and the dog handler will not know the nature of the samples. Test results will be compared with the notes of the blind-setter after all the experiments have been performed. The sensitivity and specificity of identification will be calculated. The study aims to test the hypothesis that the diagnostic sensitivity of sniffer dogs in identifying PD patients from non-PD subjects is over 90%.

Study Type

Observational

Enrollment (Actual)

1198

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hunan
      • Changsha, Hunan, China, 410008
        • Xiangya Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

PD patients and other subjects in clinics

Description

Inclusion Criteria:

  • Clinically established PD patients
  • Clearly non-PD subjects will be recruited as controls

Exclusion Criteria:

  • subjects with tremor or decrease of olfactory power or with rapid eye movement sleep behavior, obvious constipation, and depression.
  • subjects who are taking antipsychotics.
  • subjects with incomplete data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Participants with PD
patients with clinically diagnosed Parkinson's disease
Participants without PD
participants clinically diagnosed without Parkinsons' Disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The specificity and sensitivity of the identification of PD patients from non-PD by at least 2 out of 3 sniffer dogs
Time Frame: Samples taken at the time of participant enrolment and assessed by the sniffer dogs within 20 weeks

Sensitivity = number of samples of PD patients that were correctly identified by dogs/[number of samples of PD patients that were correctly identified+ number of samples of PD patients missed by the dogs]. One sample will be taken per patient.

Specificity = number of samples of non-PD subjects that were correctly identified by dogs/[number of samples of non-PD subjects that were correctly identified by dogs + number of non-PD subjects that were identified as PD]. One sample will be taken per subject.

Samples taken at the time of participant enrolment and assessed by the sniffer dogs within 20 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess the accuracy of identification by sniffer dogs for PD patients with disease duration over five years and for those with disease duration within five years of diagnosis.
Time Frame: Samples taken at the time of participant enrolment and assessed by the sniffer dogs within 20 weeks
Calculate sensitivity and specificity as mentioned above, but in two sub-populations: 1. PD patients with disease duration within 5 years and their control subjects; 2. PD patients with disease duration over 5 years and their control subjects.
Samples taken at the time of participant enrolment and assessed by the sniffer dogs within 20 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Chang-Qing Gao, MD,PhD, Xiang-Ya Hospital, Central South University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2020

Primary Completion (Actual)

January 22, 2021

Study Completion (Actual)

January 22, 2021

Study Registration Dates

First Submitted

October 28, 2020

First Submitted That Met QC Criteria

October 28, 2020

First Posted (Actual)

November 3, 2020

Study Record Updates

Last Update Posted (Actual)

September 27, 2021

Last Update Submitted That Met QC Criteria

September 21, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

3
Subscribe